Using the Prescription Monitoring Program in Substance Use Disorder Cases

## Objectives

- Discuss the statistics concerning opioid abuse and misuse
- Describe the role of the regulatory board in the opioid epidemic
- Examine the prescription drug monitoring program (PDMP)
- Demonstrate documentation of PDMP findings in an investigative report
- Recognize the limitations of the PDMP


## Why The Concern?

Prescription drugs are misused \& abused more often than any other drug, except marijuana \&
 Retrieved from http://www.samhsa.gov/disorders/substance-use
C. Since 1999, opiate overdose deaths have increased 265\% among men and 400\% among
WOी巳 Substance Abuse and Mental Health Services Administration [SAMHSA]. (2015). Substance Use Disorders. Retrieved from http://www.samhsa.gov/disorders/substance-use
10 of highest prescribing states for painkillers are in the South

United States Department of Justice (2011). State prescription drug monitoring

## 2012 Prescriptions



## Nationwide

Prescription drugs are the second most frequently abused drug category after marijuana
http://www.painmed.org/advocacy/rems/opioid-risk-evaluation-and-mitigation-strategies-rems-update/

- Approximately 15,000 people die every year from overdoses involving prescription pain killers, more than those who die from heroin

Painkiller Overdoses in the U.S. Retrieved from http://www.cdc.gov/Features/VitalSigns/PainkillerOverdoses/index.html


## Overdose Deaths Involving Opioid Analgesics, Cocaine and Heroin: United States, 1999-2010



Note: Not all overdose deaths specify the drug(s) involved, and a death may involve more than one specific substance. The rise in 2005-2006 in opioid deaths is related to non-pharmaceutical fentanyl (see
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5729a1.htm). *Heroin includes opium.
Source: Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999.
2010 on CDC WONDER Online Database, released 2012. Extracted on February 11, 2013..

10 Leading Causes of Death, United States 2013, All Races, Both Sexes

|  | Age Groups |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Rank | <1 | 1-4 | 5-9 | 10-14 | 15-24 | 25-34 | 35-44 | 45-54 | 55-64 | 65+ | All Ages |
| 1 | Congenital Anomalies 4,758 | Unintentional Injury 1,316 | Unintentional Injury 746 | Unintentional Injury 775 | Unintentional <br> Injury <br> 11,619 | Unintentional Injury 16,209 | Unintentional Injury 15,354 | Malignant <br> Neoplasms <br> 46,185 | Malignant Neoplasms 113,324 | Heart Disease 488.156 | Heart Disease 611.105 |
| 2 | Short Gestation 4,202 | Congenital Anomalies 476 | Malignant Neoplasms 447 | Malignant Neoplasms 448 | $\begin{gathered} \text { Suicide } \\ 4,878 \end{gathered}$ | $\begin{gathered} \text { Suicide } \\ 6,348 \end{gathered}$ | Malignant <br> Neoplasms <br> 11,349 | Heart Disease 35,167 | Heart Disease 72,568 | Malignant <br> Neoplasms <br> 407,558 | Malignant Neoplasms 584,881 |
| 3 | Maternal Pregnancy Comp. 1,595 | $\begin{gathered} \text { Homicide } \\ 337 \end{gathered}$ | Congenital Anomalies 179 | $\begin{gathered} \text { Suicide } \\ 386 \end{gathered}$ | $\begin{gathered} \text { Homicide } \\ 4,329 \end{gathered}$ | $\begin{gathered} \text { Homicide } \\ 4,236 \end{gathered}$ | Heart <br> Disease 10,341 | Unintentional <br> Injury <br> 20,357 | Unintentional Injury 17,057 | Chronic Low. Respiratory Disease 127,194 | Chronic Low. Respiratory Disease 149,205 |
| 4 | $\begin{aligned} & \text { SIDS } \\ & 1,563 \end{aligned}$ | Malignant Neoplasms 328 | $\begin{gathered} \text { Homicide } \\ 125 \end{gathered}$ | Congenital Anomalies 161 | Malignant Neoplasms 1,496 | Malignant Neoplasms 3,673 | $\begin{gathered} \text { Suicide } \\ 6,551 \end{gathered}$ | Liver Disease 8,785 | Chronic Low. <br> Respiratory <br> Disease <br> 15,942 | Cerebrovascular 109,602 | Unintentional Injury 130,557 |
| 5 | Unintentional Injury 1,156 | $\begin{gathered} \text { Heart } \\ \text { Disease } \\ 169 \end{gathered}$ | Chronic Low. Respiratory Disease 75 | $\begin{gathered} \text { Homicide } \\ 152 \end{gathered}$ | Heart Disease 941 | Heart Disease 3,258 | $\begin{gathered} \text { Homicide } \\ 2,581 \end{gathered}$ | $\begin{gathered} \text { Suicide } \\ 8,621 \end{gathered}$ | Diabetes Mellitus 13,061 | Alzheimer's Disease 83,786 | Cerebrovascular 128,978 |
| 6 | Placenta <br> Cord <br> Membranes <br> 953 | Influenza \& Pneumonia 102 | Heart Disease 73 | Heart Disease 100 | Congenital Anomalies 362 | Diabetes Mellitus 684 | Liver Disease 2,491 | Diabetes Mellitus 5,899 | $\begin{gathered} \text { Liver } \\ \text { Disease } \\ 11,951 \end{gathered}$ | Diabetes Mellitus 53,751 | Alzheimer's <br> Disease 84,767 |
| 7 | Bacterial Sepsis 578 | Chronic Low. Respiratory Disease 64 | Influenza \& Pneumonia 67 |  <br> Chronic Low. <br> Respiratory <br> Disease <br> 80 | Influenza <br> \& Pneumonia 197 | $\begin{aligned} & \text { Liver } \\ & \text { Disease } \\ & 676 \end{aligned}$ | Diabetes Mellitus 1,952 | Cerebrovascular 5,425 | Cerebrovascular 11,364 | Influenza <br> \& Pneumonia 48,031 | Diabetes Mellitus 75,578 |
| 8 | $\begin{array}{\|c} \text { Respiratory } \\ \text { Distress } \\ 522 \end{array}$ | $\begin{gathered} \text { Septicemia } \\ 53 \end{gathered}$ | Cerebrovascular 41 | Influenza \& Pneumonia 61 | Diabetes Mellitus 193 | $\begin{aligned} & \text { HIV } \\ & 631 \end{aligned}$ | Cerebrovascular 1,687 | Chronic Low. <br> Respiratory <br> Disease <br> 4,619 | Suicide $7,135$ | Unintentional Injury 45,942 | Influenza \& Pneumonia 56,979 |
| 9 | Circulatory <br> System <br> Disease <br> 458 | Benign Neoplasms 47 | Septicemia 35 | Cerebrovascular 48 | Complicated Pregnancy 178 | Cerebrovascular 508 | $\begin{gathered} \text { HIV } \\ 1,246 \end{gathered}$ | $\begin{aligned} & \text { Septicemia } \\ & 2,445 \end{aligned}$ | $\begin{array}{\|c} \text { Septicemia } \\ 5,345 \end{array}$ | Nephritis 39,080 | Nephritis 47,112 |
| 10 | $\begin{array}{\|c} \text { Neonatal } \\ \text { Hemorrhage } \\ 389 \end{array}$ | Perinatal Period 45 | Benign Neoplasms 34 | Benign Neoplasms 31 | Chronic Low. Respiratory Disease 155 | Influenza <br> \& Pneumonia 449 | Influenza \& Pneumonia 881 | $\underset{2,378}{\operatorname{HIV}}$ | Nephritis 4,947 | $\begin{gathered} \text { Septicemia } \\ 28,815 \end{gathered}$ | Suicide $41,149$ |

Produced By: Office of Statistics and Programming, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention Data Source: National Center for Health Statistics (NCHS), National Vital Statistics System

## Diversion as a Business

Oxycodone \& Hydrocodone sell for $\$ 20-\$ 80$ per pill "on the street" based on dose \& formulation


## drug street prices

* hydromorphone (dilaudid ${ }^{\star} 4 \mathrm{mg}$ ) $\$ 60$
* hydrocodone (vicodin ${ }^{\circledR}$, lortab ${ }^{\oplus}$, lorcet ${ }^{\circledR}$ \$6-\$8
* oxycodone (percodan ${ }^{\oplus}$, percocet ${ }^{\oplus}$ ) \$6-\$8
* oxycontin ${ }^{\text {® }} \$ .50-\$ 1 / m g$
* roxicodone 30mg \$20+
* fentanyl patches from $\$ 25$ to $\$ 100$ for $\mathbf{2 5 m c g} / \mathrm{hr}$ to 100 mcg
hr for brand, generics \$15-\$40 \$15 -\$40
* actiq $^{\text {® }} \quad \$ 8$
* methadone wafers $\$ 6$ - $\mathbf{~ 1 0 , ~ \$ 4 0 ~ i n ~ s o m e ~ a r e a s ~}$
* APAP w/codeine (tylenol ${ }^{\circledR}$ \#3/\#4) \$3 -\$5
* propoxyphene (darvocet ${ }^{\oplus} \mathrm{N}-100$ ) \$2-\$4
* serostim \$1000 - \$2000 per week supply

Overdose deaths per 100,000



## Geographically

Overdose death rates rural areas now higher than rate in large metropolitan areas, which historically had higher rates

## 15 per 100,000



Overdose deaths

## Who Does the Epidemic Affect?

DEATHS FROM DRUG OVERDOSE and other accidental poisonings have remained
.. 50 DEATHS per 100,000
relatively flat for blacks and Hispanics but continue to rise sharply among whites.
Prescription painkillers and heroin are thought to be driving the increase in drug deaths.


Source: Centers for Disease Control and Prevention

## Rates Of Opioids Sales \& Related Deaths/Treatment Admissions



## Drug Overdose Deaths Involving Opioids, By Type Of Opioid In U.S. 2000-2014



Source: National Vital Statistics System, Mortality file.

## Methadone = Painkiller Use \& Abuse

- Methadone accounts for 1 in 3 prescription painkiller overdose deaths in the U.S. (coc, 2012)
- 5,000 people die every year of overdoses related to methadone (coc, 2012)
6 times as many people died of methadone overdoses in 2009 than a decade before (cdc, 2012)



# Definition: <br> Prescription Drug Monitoring Program (PDMP) 

A PDMP is a statewide electronic database that tracks all controlled substance prescriptions. Authorized users can access prescription data such as medications dispensed, prescribers, quantity, and doses.

## Role of the Regulatory Board

Investigate health care professionals who prescribe/dispense/abuse prescription controlled substances

Help reduce prescription drug misuse, abuse, and diversion

Request PDMP data as evidence for an existing investigation, typically need a subpoena for the information

## PDMP Reports Available to Licensing/Regulatory Boards



## PDMPs Improve Patient Safety Tool for Clinicians \& Regulators

- Identify individuals obtaining opioids from multiple providers
- Calculate the total amount of opioids prescribed per day
- Identify individuals who are being prescribed other substances that may increase the risks of opioids-such as benzodiazepines


## Combined controlled substances intensify desired effect

Common combinations include:
opiate + benzodiazepine + muscle relaxant $=$ drug "cocktail"

"Trio" or "Trinity"
"Holy Trinity"

## PDMP Data May Assist Regulatory Agencies by Identifying

- Prescriptions for controlled substances II-IV (or IV)
- Abuse patterns of use
- Overprescribing of controlled substances
* Over use of controlled substances
- Multiple prescribers
- Early refills



## PDMP Data May Assist Regulatory Agencies by Identifying

- Multiple pharmacies

If prescriptions are consistent with medical records If UDS is consistent


- If substances are Rx for legitimate purpose

Known "Cocktails"
Compliance \& abstinence in monitoring programs

## What in the PDMP is Confidential?

-. Must have nexus to case \& ensure confidentiality \& security of the data
?. All aspects of the investigative report are considered confidential, which include:

- data collection
- storage
- transmission of requests
-. dissemination of reports


## CASE STUDY 1

tHE PRESCRIBER

Arizona CSPMP Prescription Drug Monitoring Program
Arizona State Board of Pharmacy, 1616 W. Adams, Suite 120, Phoenix, AZ 85007
Phone:855-929-4767 Email:azrxreporting@appriss.com Fax:866-282-7076
Patient RX History Report

This report may contain more than one patient's prescription information. Please review the "Patients that Match Search Criteria" section below to ensure all prescriptions belong to the requested patient.

Search Criteria: First Name =
And Last Name = And D.O.B. $=06 / 24 / 1991$ And State $=$ AZ And Request Period '01/01/2010' To '10/27/2015'

Patients that match search criteria

| Pt ID | Name | DOB | Address |
| :---: | :---: | :---: | :---: |
| 5538 | $\square$ | 06/24/1991 | 10888 N 70TH ST APT 145 SCOTTSDALE AZ 85254 |
| 2772 | $\square$ | 06/24/1991 | 5207 W EL CAMINITO DRIVE GLENDALE AZ 85302 |
| 3560 | $\square$ | 06/24/1991 | 5207 W El Caminito Dr Glendale AZ 853026211 |
| 6246 | - | 06/24/1991 | 5207 W EL CAMINITO DR GLENDALE AZ 85302 |

## Prescriptions

| Fill Date | Product, Str, Form | Quantity | Days | Pt ID | Prescriber | Written | Rx \# | $\begin{array}{\|l\|l} \hline \text { Daily } \\ \text { MED } \end{array}$ | Active ${ }^{2}$ | $N / R$ | Pharm | Pay |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 09/29/2015 | ALPRAZOLAM, 2 MG, TABLET | 80.00 | 30 | 3560 | MJ2353996 | 09/29/2015 | 4408328 | - | Y | N | FW2386147 | 04 |
| 09/17/2015 | ALPRAZOLAM, 2 MG, TABLET | 30.00 |  | 3560 | BS3319604 | 09/17/2015 | 4408242 | - | N | N | FW2386147 | 04 |
| 08/24/2015 | ALPRAZOLAM, 2 MG, TABLET | 90.00 |  | 3560 | MJ2353996 | 08/24/2015 | 4408093 | - | N | N | FW2386147 | 04 |
| 07/27/2015 | ALPRAZOLAM, 2 MG, TABLET | 95.00 |  | 3560 | MJ2353996 | 07/27/2015 | 4407904 | - | N | N | FW2386147 | 04 |
| 06/29/2015 | ALPRAZOLAM, 2 MG, TABLET | 100.00 |  | 3560 | MJ2353996 | 06/29/2015 | 4407726 | - | N | N | FW2386147 | 04 |


| Fill Date | Product, Str, Form |
| :--- | :--- |
| $09 / 29 / 2015$ | ALPRAZOLAM, 2 MG, TABLET |
| $09 / 17 / 2015$ | ALPRAZOLAM, 2 MG, TABLET |
| $08 / 24 / 2015$ | ALPRAZOLAM, 2 MG, TABLET |
| $07 / 27 / 2015$ | ALPRAZOLAM, 2 MG, TABLET |
| $06 / 29 / 2015$ | ALPRAZOLAM, 2 MG, TABLET |


| Quantity | Days | Pt ID | Prescriber | Written |
| :---: | :---: | :---: | :---: | :---: |
| 80.00 | 30 | 3560 | MJ2353996 | 09/29/201 ${ }^{\text {r }}$ |
| 30.00 | 8 | 3560 | BS3319604 | 09/17/20 |
| 90.00 | 23 | 3560 | MJ2353996 | 08/24/201. |
| 95.00 | 24 | 3560 | MJ2353996 | 07/27/201b |
| 100.00 | 25 | 3560 | MJ2353996 | 06/29/2015 |


| Fill Date | Product, Str, Form | Quantity | Days | Pt ID | Prescriber | Written | Rx \# | $\begin{aligned} & \text { Daily } \\ & \text { MED }^{1} \\ & \hline \end{aligned}$ | Active ${ }^{2}$ | N/R | Pharm | Pay |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 09/29/2015 | ALPRAZOLAM, 2 MG, TABLET | 80.00 | 30 | 3560 | MJ2353996 | 09/29/2015 | 4408328 | - | Y | N | FW2386147 | 04 |
| 09/17/2015 | ALPRAZOLAM, 2 MG, TABLET | 30.00 | 8 | 3560 | BS3319604 | 09/17/2015 | 4408242 | - | N | N | FW2386147 | 04 |
| 08/24/2015 | ALPRAZOLAM, 2 MG, TABLET | 90.00 | 23 | 3560 | MJ2353996 | 08/24/2015 | 4408093 | - | N | N | FW2386147 | 04 |
| 07/27/2015 | ALPRAZOLAM, 2 MG, TABLET | 95.00 | 24 | 3560 | MJ2353996 | 07/27/2015 | 4407904 | - | N | N | FW2386147 | 04 |
| 06/29/2015 | ALPRAZOLAM, 2 MG, TABLET | 100.00 | 25 | 3560 | MJ2353996 | 06/29/2015 | 4407726 | - | N | N | FW2386147 | 04 |
| 06/02/2015 | ALPRAZOLAM, 2 MG, TABLET | 105.00 | 27 | 6246 | MJ2353996 | 06/02/2015 | 4195703 | - | N | N | BS6377003 | 04 |
| 05/05/2015 | ALPRAZOLAM, 2 MG, TABLET | 110.00 | 27 | 3560 | MJ2353996 | 05/05/2015 | 4195307 | - | N | N | BS6377003 | 04 |
| 04/09/2015 | ALPRAZOLAM, 2 MG, TABLET | 110.00 | 27 | 3560 | MJ2353996 | 02/27/2015 | 4194289 | - | N | N | BS6377003 | 04 |
| 03/16/2015 | ALPRAZOLAM, 2 MG, TABLET | 110.00 | 28 | 3560 | MJ2353996 | 03/16/2015 | 4407059 | - | N | N | FW2386147 | 04 |
| 02/26/2015 | ALPRAZOLAM, 2 MG, TABLET | 90.00 | 22 | 3560 | MJ2353996 | 01/23/2015 | 4193658 | - | N | R | BS6377003 | 04 |
| 01/30/2015 | ALPRAZOLAM, 2 MG, TABLET | 120.00 | 30 | 3560 | MJ2353996 | 01/23/2015 | 4193658 | - | N | R | BS6377003 | 04 |
| 01/23/2015 | ALPRAZOLAM, 2 MG, TABLET | 30.00 | 7 | 3560 | MJ2353996 | 01/23/2015 | 4193658 | - | N | N | BS6377003 | 01 |
| 01/06/2015 | ALPRAZOLAM, 2 MG, TABLET | 120.00 | 30 | 3560 | MJ2353996 | 12/10/2014 | 4406473 | - | N | R | FW2386147 | 04 |
| 12/10/2014 | ALPRAZOLAM, 2 MG, TABLET | 120.00 | 30 | 3560 | MJ2353996 | 12/10/2014 | 4406473 | - | N | N | FW2386147 | 04 |
| 11/18/2014 | ALPRAZOLAM, 1 MG, TABLET | 120.00 | 30 | 3560 | MJ2353996 | 10/22/2014 | 4192179 | - | N | R | BS6377003 | 04 |
| 10/22/2014 | ALPRAZOLAM, 1 MG, TABLET | 120.00 | 30 | 3560 | MJ2353996 | 10/22/2014 | 4192179 | - | N | N | BS6377003 | 04 |
| 09/22/2014 | ALPRAZOLAM, 1 MG, TABLET | 120.00 | 30 | 3560 | MJ2353996 | 09/22/2014 | 4191641 | - | N | N | BS6377003 | 04 |
| 07/29/2014 | LORAZEPAM, .5 MG , TABLET | 60.00 | 15 | 2772 | MJ2353996 | 07/29/2014 | 4405586 | - | N | N | FW2386147 | 04 |
| 09/10/2012 | HYDROCODONE BITARTATE AND ACETAMINOPHEN, 325 MG;5 MG, TABLET | 15.00 | 1 | 5538 | BC7179991 | 09/10/2012 | 2134113 | 75.00 | N | N | BW4115653 | 01 |
| 08/22/2012 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN, 500 MG;5 MG, TABLET | 20.00 | 2 | 5538 | BS2099198 | 08/22/2012 | 2128573 | 50.00 | N | N | BW4115653 | 01 |
| 03/16/2010 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN, 500 MG;5 MG, TABLET | 20.00 | 1 | 5538 | BK6843216 | 03/16/2010 | 0045436553 | 100.00 | N | N | BT4478310 | 04 |
| 03/16/2010 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN, 500 MG;5 MG, TABLET | 20.00 | 1 | 5538 | BK6843216 | 03/16/2010 | 4425563 | 100.00 | N | N | BT4478310 | 04 |

## N/R, Pay Codes, M.E.D.

Pay:
01=Private Pay
02=Medicaid
03=Medicare
04=Commercial Ins.
05=Military Inst. and VA
06=Workers Comp
07=Indian Nations
99=Other

Daily MED : The morphine equivalent per day for the individual prescription based on CDC conversion chart, the days supply and quantity dispensed provided by the pharmacy.
Snapshot of the day that the report is run
N/R: N=New R=Refill

## Prescribers/Pharmacies

Prescribers for prescriptions listed


## Written Report

## AZ CSPMP Profile for Patient C

## Requested timeframe: $1 / 1 / 2010$ through 8/27/15

- Review prescription profile for Patient C indicted Respondent was the primary prescriber (with 2 exceptions).
- From around July 2014 - September 27, 2015, Patient C received six (6) early refills of alprazolam (Xanax) 2 mg .
- For June \& July 2015, Respondent prescribed Xanax 2mg, totaling 300 tablets in around 60 days, averaging ( 5 tablets) ( 10 mg ) of Xanax daily.


## CASE STUDY 2

 NURSE \#1 WITH SUDThis report may contain more than one patient's prescription information. Please review the "Patients that Match Search Criteria" section below to ensure all prescriptions belong to the requested patient.

Search Criteria: First Name $=$
And Last Name $=$
And D.O.B. $=$ 05/07/1981 And State $=$ AZ And Request Period '01/01/2010' To '10/27/2015'

## Patients that match search criteria

| Pt ID | Name | DOB | Address |
| :---: | :---: | :---: | :---: |
| 3567 | - | 05/07/1981 | 1967 N 104th Dr Avondale AZ 85392 |
| 4290 | 0-2 0 | 05/07/1981 | 1967 N 104th Dr Avondale AZ 85392 |
| 1527 | $\square$ | 05/07/1981 | 1967 N 104th Dr Avondale AZ 85392 |
| 4324 | - | 05/07/1981 | 1967 N 104th Dr Avondale AZ 853924759 |
| 2289 | -2xen | 05/07/1981 | 6364 W Golden Ln Glendale AZ 85302442 |
| 1258 | -2 | 05/07/1981 | 1967 N 104TH DR AVONDALE AZ 85392 |
| 3617 | 0 - 10 | 05/07/1981 | 6364 W. GOLDEN LN Phoenix AZ 85032 |
| 6320 | - 0 ? | 05/07/1981 | 1967 N 104TH DR AVONDALE AZ 85392 |
| 6321 | $\underline{\square}$ | 05/07/1981 | 1967 N 104TH DR AVONDALE AZ 85392 |
| 3365 | $\square$ | 05/07/1981 | 6364 W GOLDEN LANE GLENDALE AZ 85302 |
| 2204 | $\square 0$ | 05/07/1981 | 2770 E Van Buren St Phoenix AZ 850086088 |
| 2777 | $\square$ | 05/07/1981 | 5315 W MOUNTAIN VIEW RD GLENDALE AZ 85302 |
| 1289 | - | 05/07/1981 | 5315 W Mountain View Rd Glendale AZ 853022201 |
| 0587 | neme nemen | 05/07/1981 | 6364 W Golden Ln Glendale AZ 853024434 |
| 7902 | -209 | 05/07/1981 | 6364 W GOLDEN LN GLENDALE AZ 85302 |
| 4171 | - | 05/07/1981 | 1967 N. 104TH DR. AVONDALE AZ 85323 |
| 3616 | 20es -mmen | 05/07/1981 | 1967 N 104TH DR AVONDALE AZ 85392 |

## Multiple Prescribers

| Fill Date | Product, Str, Form | Quantity | Days Pt ID | Prescriber | Written | Rx\# | Daily MED ${ }^{1}$ | Active ${ }^{2}$ | N/R | Pharm | Pay |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 03/24/2010 | OXYCODONE HYDROCHLORIDE CONTROLLED-RELEASE, 10 MG, TABLET, EXTENDED RELEASE | 10.00 | 103616 | MS1734462 | 03/24/2010 | 1651829 | 15.00 | N | N | AW0572506 | 01 |
| 03/15/2010 | OXYCONTIN, $40 \mathrm{MG}, \mathrm{TER}$ | 42.00 | 213616 | MG1730806 | 03/15/2010 | 1780824 | 120.00 | $N$ | $N$ | BW3793191 | 04 |
| 03/06/2010 | OXYCODONE HYDROCHLORIDE CONTROLLED-RELEASE, 10 MG, TABLET, EXTENDED RELEASE | 30.00 | 303616 | MS1734462 | 03/05/2010 | 1646294 | 15.00 | N | N | AW0572506 | 04 |
| 03/05/2010 | OXYCONTIN, 40 MG , TER | 60.00 | 303616 | MS1734462 | 03/05/2010 | 1646322 | 120.00 | $N$ | $N$ | AW0572506 | 04 |
| 02/04/2010 | OXYCONTIN, $10 \mathrm{MG}, \mathrm{TER}$ | 30.00 | 303616 | MK1649764 | 12/04/2010 | 830410 | 15.00 | $N$ | N | BW6197897 | 04 |
| 02/04/2010 | OXYCONTIN, 40 MG , TER | 60.00 | 303616 | MK1649764 | J2/04/2010 | 830411 | 120.00 | $N$ | N | BW6197897 | 041 |

## $F_{i n 12}^{212}$

## Cash Pay

| Fill Date | Product, Str, Form | Quantity | Days | Pt ID | Prescriber | Written | Rx \# | $\begin{array}{\|l\|} \hline \text { Daily } \\ \text { MED } \\ \hline \end{array}$ | Active ${ }^{2}$ | N/R | Pharm P | Pay |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 12/22/2010 | OXYCODONE HYDROCHLORIDE, 15 MG, TABLET | 120.00 |  | 304171 | AB8864200 | 12/22/2010 | 47743 | 90.00 | N | N | BX9625560 | 01 |
| 12/09/2010 | OXYCODONE HYDROCHLORIDE, 40 MG , TER | 60.00 |  | 306320 | B.9822443 | 12/06/2010 | 1901005 | 120.00 | N | N | BW3793177 | 04 |
| 1209/2010 | OXYCODONE HCL, $15 \mathrm{MG}, \mathrm{TAB}$ | 150.00 |  | 306320 | BV9822443 | 12/06/2010 | 2432925 | 112.50 | $N$ | N | AW0572518 | 04 |
| 11/10/2010 | OXYCODONE HCL, $15 \mathrm{MG}, \mathrm{TAB}$ | 120.00 |  | 305784 | B.9822443 | 11/10/2010 | 163237 | 90.00 | $N$ | N | BE9738026 | 04 |
| 11/10/2010 | OXYCONTIN, 40 MG, TABLET, FLLM COATED, EXTENDED RELEASE | 60.00 |  | 305784 | BV9822443 | 11/10/2010 | 163240 | 120.00 | $N$ | N | BE9738026 | 04 |
| 11/08/2010 | FENTANYL, 50 UG/H, PATCH, EXTENDED RELEASE | 5.00 |  | 145784 | B.9822443 | 11/08/2010 | 163029 | 128.57 | $N$ | $N$ | BE9738026 | 01 |
| 11/08/2010 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 2.00 |  | 25784 | B,9822443 | 11/08/2010 | 163042 | 45.00 | $N$ | $N$ | BE9738026 | 01 |
| 10/27/2010 | OXYCONTIN, 60 MG, TABLET, FLLM COATED, EXTENDED RELEASE | 30.00 |  | 156320 | BL7863245 | 10/27/2010 | 1661576 | 180.00 | $N$ | N | BW4612227 | 04 |
| 09/20/2010 | OXYCONTIN, 60 MG, TABLET, FLLM COATED, EXTENDED RELEASE | 60,00 |  | 306320 | BL7863245 | 09/20/2010 | 625422 | 180.00 | $N$ | N | BW8157819 | 04 |
| 08/23/2010 | OXYCONTIN, 60 MG, TER | 60.00 |  | 303616 | BL7863245 | 08/23/2010 | 616955 | 180.00 | $N$ | $N$ | BW8157819 | 04 |
| 07/28/2010 | OXYCODONE HYDROCHLORIDE, 10 MG , TER | 30.00 |  | 306321 | BL7863245 | 07/28/2010 | 609850 | 15.00 | $N$ | $N$ | BW8157819 | 04 |
| 07/28/2010 | OXYCONTIN, 40 MG , TER | 60,00 |  | 306321 | BL7863245 | 07/28/2010 | 609851 | 120.00 | $N$ | $N$ | BW8157819 | 04 |


| Fill Date | Product, Str, Form | Quantity | Days | Pt ID | Prescriber | Written | Rx\# | ily | Active ${ }^{2}$ | N/R | Pharm | Pay |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | r |  |  | MED ${ }^{1}$ |  |  |  |  |
| 09/06/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 180.00 |  | 2666 | FS0607385 | 09/08/2012 | 207890 | 270.00 | N | N | BA9730652 | 01 |
| 08/24/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 120.00 | 30 | 1527 | AR7497541 | 08/24/2012 | 021-98965 | 180.00 | $N$ | N | FA1240693 | 04 |
| 07/30/2012 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN, 325 MG;7.5 MG, TABLET | 40.00 |  | 4127 | B84445018 | 07/26/2012 | 639211 | 100.00 | N | N | BW7326499 | 04 |
| 07/26/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 120.00 |  | 1527 | AR7497541 | 07/26/2012 | 021-97749 | 180.00 | $N$ | $N$ | FA1240693 | 04 |
| 07/21/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 180.00 |  | 3039 | FS0607385 | 07/11/2012 | 63698 | 270.00 | $N$ | N | BX9625560 | 01 |
| 07/11/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 180.00 |  | 2666 | FS0607385 | 07/11/2012 | 207507 | 270.00 | $N$ | N | BA9730652 | 04 |
| 06/28/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 120.00 |  | 3039 | AR7497541 | 06/28/2012 | 63149 | 225.00 | N | N | BX9625560 | 04 |
| 06/15/2012 | OXYCODONE HYDROCHLORIDE, $30 \mathrm{MG}, \mathrm{TABLET}$ | 180.00 |  | 1527 | FS0607385 | 06/15/2012 | 021-96037 | 270.00 | $N$ | N | FA1240693 | 04 |
| 05/31/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 120.00 |  | 2666 | AR7497541 | 05/31/2012 | 207155 | 216.00 | $N$ | $N$ | BA9730652 | 04 |
| 05/17/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 180.00 |  | 3039 | FS0607385 | 05/17/2012 | 62164 | 270.00 | $N$ | N | BX9625560 | 01 |
| 05/08/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 150.00 |  | 2666 | AR7497541 | 05/08/2012 | 206937 | 225.00 | N | $N$ | BA9730652 | 04 |
| 04/24/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 180.00 |  | 1527 | FS0607385 | 04/24/2012 | 021-93710 | 270.00 | $N$ | N | FA1240693 | 04 |
| 04/10/2012 | OXYCODONE HYDROCHLORIDE, 30 MG , TABLET | 150.00 |  | 2666 | AR7497541 | 04/10/2012 | 206689 | 270.00 | N | N | BA9730652 | 04 |

## Written Report

Consultant/Investigator Note: From April - December 2010 Respondent received controlled substances from a minimum of eight (8) different providers, receiving monthly refills for the same medications (oxycodone and oxycontin).
Respondent refilled prescriptions early on 17 occasions \& paid cash at 4 different pharmacies with dosages \& quantities progressively increasing.


## CASE STUDY 3

NURSE \#2 WITH SUD
saz

## Written Report

| Date filled | Days between Rx filled | Days early for <br> refill | Drug | Qty. | Days' <br> supply | Date written | Rx. \# |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| $07 / 08 / 2012$ | 12 days from last fill |  | Lorazepam, 1 Mg | 60 | 30 | $04 / 27 / 2012$ | 2159986 |
| $06 / 26 / 2012$ | 8 days from last fill | 22 days early | Diazepam, 10 Mg | 30 | 10 | $06 / 26 / 2012$ | 4433627 |
| $06 / 18 / 2012$ | 8 days from last fill | 37 days early | Diazepam, 10 Mg | 90 | 30 | $05 / 25 / 2012$ | 4433376 |
| $06 / 10 / 2012$ | 10 days from last fill | 20 days early | Diazepam, 10 Mg | 90 | 45 | $05 / 09 / 2012$ | 2150609 |
| $05 / 30 / 2012$ | 21 days from last fill | 24 days early | Diazepam, 10 Mg | 90 | 30 | $05 / 25 / 2012$ | 4433376 |
| $05 / 09 / 2012$ | 19 days from last fill | 11 days early | Diazepam, 10 Mg | 90 | 45 | $05 / 09 / 2012$ | 2023949 |
| $04 / 20 / 2012$ | 20 days from last fill | 10 days early | Lorazepam, 0.5 Mg | 60 | 30 | $04 / 20 / 2012$ | 2019081 |
| $03 / 30 / 2012$ | 12 days from last fill | 9 days early | Lorazepam, 0.5 Mg | 60 | 30 | $03 / 30 / 2012$ | 2013629 |
| $03 / 08 / 2012$ |  |  | Lorazepam, 0.5 Mg | 60 | 30 | $03 / 08 / 2012$ | 2007975 |

## az

## Written Report

## AZ Controlled Substance Prescription Monitoring Program Report Timeframe: Jan 2010 - May 2014

Review of Respondent's PMP profile revealed:

- From around 2010-2012, Respondent had a history of receiving escalating doses of oxycodone from multiple providers, with frequent early refills.
- For example, February 2011, Respondent received 104 tablets of oxycodone from two different providers and in March 2011, she received 270 tablets of oxycodone from 3 different providers.
- For the period of 2010-2011, Respondent had received only two prescriptions for a benzodiazepine, (Valium 5mg) totaling 40 tablets.


## Reminders

Nexus Identify your nexus
Tool Remember the
Patterns Identify patterns
$\$ \$ \$$ Consider self use or street value
original Obtain a copy of the original prescription

## az $16 n$

## How to use PDMP

## CAUTION

- Verify Recipient
- Verify quantities
- Verify Rx was actually picked up
- Request Medical Records
- Compare PDMP to medical Record
- Request prescription profiles from pharmacy and and insurance companies


## PDMP Limitations


-. Human error when entered
Illegible prescriber name
"Date Filled" may differ
-. Person may access drug across state boarders
2 week lag in data entry

## Entities that DO NOT Contribute to PDMP

Federal Facilities include:

- Department of

Veterans affairs

- Department of

Defense

- Indian Health Services on


## U.S. Department of Veterans Affairs Pharmacies Reporting to PDMP

* To view the V A Pharmacy sites, hover the mouse pointer over the state



## Sharing PDMP Information

Authorized PMP users state with valid MOU may gain access to interstate data by logging directly into the state PMP in which they are a registered user.
Several additional states intend to begin sharing data or are in the process of signing an MOU to share data using NABP InterConnect.


National Association of Boards of Pharmacy

PMP ${ }^{\text {InterConnect }}{ }^{\circ}$


Legend
NABP PMP InterConnect Participant (System Live) $\square$ Memorandum of Understanding Executed
Pending NABP PMP InterConnect Participant
$\square$ Prospective NABP PMP InterConnect Participant No PMP in Place

## Questions ???

JDahn@azbn.gov 602-771-7814

